SWOT Analysis of AstraZeneca 2026: Strengths, Weaknesses, Opportunities and Threats
A SWOT analysis of AstraZeneca built on the FY2025 results, the Annual Report and Form 20-F and the H1 2026 announcement: oncology at 44 percent of revenue, sixteen blockbusters, net debt rising to 26.9 billion dollars, the largest medicine past US exclusivity and China shrinking under volume-based procurement. Written as an MBA strategy sample with sources.
· 26 min read
Read The Sample: SWOT Analysis of AstraZeneca 2026: Strengths, Weaknesses, Opportunities and Threats